

Advanced Methods in Dose-Response Screening of Enzyme Inhibitors

Petr Kuzmič, Ph.D.
BioKin, Ltd.

TOPICS:

- 1. Fitting model:** Four-parameter logistic (IC_{50}) vs. Morrison equation (K_i^*)
- 2. Robust regression:** Implementing outlier exclusion in practice
- 3. Confidence intervals:** What should we store in activity databases?

Acknowledgements:


Craig Hill & Jim Janc
[Celera Genomics](#), Department of Enzymology and HTS




Assumptions

- We need a *portable* measure of inhibitory potency.
- Failing portability, at least we need to *rank* compounds correctly.
- For correct ranking, we need both *precision* and *accuracy*.
- No measurement is perfectly accurate: *confidence intervals*.
- Few experiments are designed ideally and executed flawlessly.


Reminder:



PRECISION



ACCURACY



PRECISION
&
ACCURACY



Dose-response screening of enzyme
inhibitors

2

Measures of inhibitory potency

INTRINSIC MEASURE OF POTENCY:

$$\Delta G = -RT \log K_i$$

DEPENDENCE ON EXPERIMENTAL CONDITIONS	Depends on [S]	Depends on [E]	Example:
			Competitive inhibitor
1. Inhibition constant	NO	NO	K_i
2. Apparent K_i	YES	NO	$K_i^* = K_i (1 + [S]/K_M)$
3. IC_{50}	YES	YES	$IC_{50} = K_i (1 + [S]/K_M) + [E]/2$


"CLASSICAL" INHIBITORS: $[E] \ll K_i$; $IC_{50} \approx K_i^*$

"TIGHT BINDING" INHIBITORS: $[E] \approx K_i$; $IC_{50} \neq K_i^*$

Tight binding inhibitors : $[E] \approx K_i$

HOW PREVALENT IS "TIGHT BINDING"?

A typical data set: $\sim 10,000$ compounds
 Completely inactive: $\sim 1,100$... NOT SHOWN
 Tight binding: ~ 400




Data courtesy of
Celera Genomics

Problem: Negative K_i from IC_{50}

FIT TO FOUR-PARAMETER LOGISTIC:

$$K_i^* = IC_{50} - [E] / 2$$



Data courtesy of
Celera Genomics




Dose-response screening of enzyme
inhibitors

5

Solution: Do not use four-parameter logistic

FIT TO MODIFIED MORRISON EQUATION: P. Kuzmic et al. (2000) *Anal. Biochem.* 281, 62-67.
P. Kuzmic et al. (2000) *Anal. Biochem.* 286, 45-50.



Data courtesy of
Celera Genomics



Dose-response screening of enzyme
inhibitors

6

Fitting model for enzyme inhibition: Summary

MEASURE OF INHIBITORY POTENCY

- Apparent inhibition constant K_i^* is preferred over IC_{50}

MATHEMATICAL MODEL

- Modified Morrison equation is preferred over four-parameter logistic

$$v = V_0 + V_0 \frac{[E] - [I] - K_i^* + \sqrt{([E] - [I] - K_i^*)^2 + 4[E]K_i^*}}{2[E]}$$

METHODOLOGY

- Optionally, adjust the enzyme concentration in fitting K_i^*


TOPICS:

1. **Fitting model:** Four-parameter logistic (IC_{50}) vs. Morrison equation (K_i^*)
 2. **Robust regression:** Implementing outlier exclusion in practice
 3. **Confidence intervals:** What should we store in activity databases?
-

Problem: Occasional "outlier" points

LEAST-SQUARES FIT

P. Kuzmic et al. (2004) *Meth. Enzymol.* 383, 66-81.




Dose-response screening of enzyme inhibitors

9

Solution: Robust regression ("IRLS")

HUBER'S "MINIMAX" METHOD

P. Kuzmic et al. (2004) *Meth. Enzymol.* 383, 66-81.



Dose-response screening of enzyme inhibitors

10


Robust fit: Practical considerations

"The devil is in the details."

- Treat negative controls in a special way (unit weight).
- Allow only a certain maximum number of "outliers".

Robust fit: Constant weighting of negative controls


NEGATIVE CONTROL WELLS ($[I] = 0$) ARE EXCLUDED FROM ROBUST WEIGHTING SCHEME



Data courtesy of
Celera Genomics

Robust fit: Limiting the number of "outliers"

I.R.L.S.: AT MOST ONE HALF OF DATA POINTS WITH NON-UNIT WEIGHTS



Data courtesy of
Celera Genomics




Dose-response screening of enzyme
inhibitors

13

Robust fit: Productivity and objectivity gains

A CASE STUDY "BEFORE AND AFTER" IMPLEMENTING ROBUST REGRESSION



Data courtesy of
Celera Genomics



Dose-response screening of enzyme
inhibitors

14

Robust fit: Summary


- Tested on 10,000+ dose response curves
- Huber's "Minimax method" proved most effective
- Modifications for inhibitor screening:
 - a. Handling of negative controls
 - b. Prevent too many outliers
- Increase in scientific *objectivity & productivity*

TOPICS:

1. **Fitting model:** Four-parameter logistic (IC_{50}) vs. Morrison equation (K_i^*)
 2. **Robust regression:** Implementing outlier exclusion in practice
 3. **Confidence intervals:** What should we store in activity databases?
-

What is the "true" value of an inhibition constant?

AVERAGE & STANDARD DEVIATION FROM 43 REPLICATES




Data courtesy of
Celera Genomics



17

Formal standard errors are too narrow

EXPERIMENT #76



Formal standard error

$$K_i^* = (11.5 \pm 1.2) \mu\text{M}$$

fit of Data 1
ation
le of results
ve
graph

2	Best-fit values	
3	VB	0.0
4	VO	100.3
5	E	0.0100
6	K	11.52
7	Std. Error	
8	VO	1.822
9	K	1.204
10	95% Confidence Intervals	
11	VO	95.94 to 104.6
12	K	8.674 to 14.37

INTERVAL **DOES NOT** INCLUDE "TRUE" VALUE 13.7 µM

Data courtesy of
Celera Genomics




Dose-response screening of enzyme
inhibitors

18

Symmetrical confidence intervals are better

EXPERIMENT #76



Symmetrical 95% confidence interval

$$K_i^* = (8.6 \dots 14.4) \mu\text{M}$$

fit of Data 1		
2	Best-fit values	
3	VB	0.0
4	VO	100.3
5	E	0.0100
6	K	11.52
7	Std. Error	
8	VO	1.822
9	K	1.204
10	95% Confidence Intervals	
11	VO	95.94 to 104.6
12	K	8.674 to 14.37

INTERVAL DOES INCLUDE "TRUE" VALUE 13.7 μM

Data courtesy of
Celera Genomics




Dose-response screening of enzyme
inhibitors

19

Nonsymmetrical confidence intervals are the best

NONSYMMETRICAL 99% C.I.

Watts, D.G. (1994) *Meth. Enzymol.* 240, 23-36.
Bates & Watts (1988) *Nonlinear Regression*, p. 207



Data courtesy of
Celera Genomics



20

Confidence intervals (C.I.): Summary

- Report two numbers for each compound: *high* and *low* end of the C.I.
- If two C.I.'s overlap, the two inhibitory activities are *indistinguishable*.
- Thus, many compounds can end up with *identical rank*!

TOPICS:

1. **Fitting model:** Four-parameter logistic (IC_{50}) vs. Morrison equation (K_i^*)
2. **Robust regression:** Implementing outlier exclusion in practice
3. **Confidence intervals:** What should we store in activity databases?

Conclusions: Toward a "best-practice" standard in secondary screening

Toward "best-practice" in secondary screening

DOSE-RESPONSE STUDIES OF ENZYME INHIBITORS

- Measure K_i^* , not IC_{50} (dependence on experimental conditions).
 - Use a mechanism-based model ([Morrison equation](#)), not the four-parameter logistic equation (no physical meaning).
 - Employ [robust regression](#) techniques, but very carefully.
 - Report a *high/low range* (confidence interval) for every K_i^* .
-